Related Experiment Video
Updated: Feb 14, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies
Felice Gragnano1, Paolo Calabrò1
1Division of Clinical Cardiology, A.O.R.N. Sant'Anna e San Sebastiano, Caserta, Italy; Department of Cardiothoracic and Respiratory Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Insights
Dual lipid-lowering therapies combining statins with ezetimibe or PCSK9 inhibitors significantly reduce LDL-C, promoting coronary atherosclerosis regression and improving cardiovascular outcomes in high-risk patients.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Despite statin therapy, many patients have high residual cardiovascular risk due to insufficient LDL-C reduction.
- Novel lipid-lowering agents are needed to enhance cardiovascular disease prevention.
Purpose of the Study:
- To review the evidence on dual lipid-lowering therapies for managing coronary atherosclerosis.
- To assess the impact of combination strategies on cardiovascular outcomes.
Main Methods:
- Review of recent clinical trials and meta-analyses.
- Focus on combination therapies including statins with ezetimibe or PCSK9 inhibitors (evolocumab, alirocumab).
Main Results:
- Combination therapy significantly lowers LDL-C levels.
- Dual therapy promotes regression of coronary atherosclerosis.
- Improved cardiovascular outcomes observed in moderate-to-high risk patients.
Conclusions:
- Dual lipid-lowering strategies are effective in managing LDL-C and coronary atherosclerosis.
- Combination therapy offers a valuable approach for patients with residual cardiovascular risk on statins.
Abstract:
Despite recent therapeutic advances, there is an unmet need in cardiovascular disease prevention. Clinical trials and meta-analyses have established that LDL-C lowering, particularly by statin therapy, reduces the progression of coronary atherosclerosis and the risk of coronary events. Insufficient LDL-C reduction and high residual risk in a significant proportion of statin-treated patients signify that additional therapies are required to deliver more effective coronary care. Pharmacological inhibition of cholesterol absorption (with ezetimibe) and PCSK9 activity (with evolocumab or alirocumab) provides potentially useful approaches for the therapeutic modulation of LDL-C metabolism in statin-treated patients. In recent trials, combination strategies involving a statin and non-statin agent (ezetimibe or evolocumab) have been shown to promote coronary atherosclerosis regression and improve cardiovascular outcomes in patients with moderate-to-high cardiovascular risk. This review summarizes recent evidence on the effects of dual lipid-lowering therapy on coronary atherosclerosis.
Related Concept Videos
Regression Toward the Mean
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
The Evidence for Evolution
Vapor Pressure Lowering
Multiple Regression
Farmers can use multiple regression to determine the crop yield based on more than one factor, such as water availability, fertilizer, soil properties, etc. Here, the crop yield is the response or dependent variable as it depends on the other independent variables. The analysis requires the construction of a scatter plot...
Correlation and Regression

